In June, a study supported by the National Cancer Institute found that for people with HIV, early treatment of precancerous anal lesions caused by human papillomavirus (HPV) can cut rates of anal cancer incidence by more than half. These findings from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study are creating secondary prevention options for those at risk for anal cancer who have not received the HPV vaccine. We look into the history of the study and what its work means for those at risk for anal cancer.
Cancer HealthCast
47m listen
An Intersectional Look at Anal Cancer and HIV
Share
NCI’s ANCHOR study discovered that early treatment of precancerous lesions can cut anal cancer rates by more than half in people with HIV.
-
Dr. Joel Palefsky Professor of Medicine University of California San Francisco -
Dr. Robert Yarchoan Director, Office of HIV and AIDS Malignancy NCI
Related Content
-
Federal Courts Use GIS to Improve Security, Visitor Experience
The Administrative Office of the Courts is using geospatial intelligence systems data to integrate security systems, enhance safety and improve the visitor experience.
13m listen -
AI Decision Support System Aims to Improve Battlefield Triage
APPRAISE helps combat medics identify hemorrhage risk earlier and make faster triage and evacuation decisions.
7m watch -
VA Deputy Secretary on Resuming EHR Rollout
VA resumed rollout of its EHRM program this weekend after a three-year pause, and Paul Lawrence discusses early feedback and lessons learned.
15m watch -
Former GSA, NASA Leader on Federal Acquisition Leadership
Former GSA and NASA executive Mary Davie shares advice for public servants considering a move to the private sector.
6m watch